Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

292

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Type 2 Diabetes
Interventions
DRUG

Sitagliptin

Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.

DRUG

Basal Bolus

Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed

DRUG

Metformin and Sitagliptin

Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.

DRUG

Glargine

"Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.~Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day."

DRUG

Glargine 50%

Glargine will be prescribed at 50% of daily hospital dose.

DRUG

Glargine 80%

Glargine will be prescribed at 80% of daily hospital dose.

Trial Locations (5)

19140

Temple University, Philadelphia

30303

Grady Memorial Hospital, Atlanta

30324

Emory University Hospital, Atlanta

43210

Ohio State University, Columbus

48109

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Temple University

OTHER

collaborator

University of Michigan

OTHER

collaborator

Ohio University

OTHER

lead

Emory University

OTHER

NCT01845831 - Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter